An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase
Zhifen Zhou,Yujing Li,Huimin Xu,Xiaowei Xie,Zibin He,Song Lin,Ruofei Li,Shouheng Jin,Jun Cui,Hai Hu,Feng Liu,Su Wu,Wenbin Ma,Zhou Songyang
DOI: https://doi.org/10.1016/j.isci.2022.103813
IF: 5.8
2022-02-01
iScience
Abstract:Most tumor cells reactivate telomerase to ensure unlimited proliferation, whereas the expression of human telomerase reverse transcriptase (<i>hTERT</i>) is tightly regulated and rate-limiting for telomerase activity maintenance. Several general transcription factors (TFs) have been found in regulating <i>hTERT</i> transcription; however, a systematic study is lacking. Here we performed an inducible CRISPR/Cas9 KO screen using an <i>hTERT</i> core promoter-driven reporter. We identified numerous positive regulators including an E3 ligase DTX2. In telomerase-positive cancer cells, DTX2 depletion downregulated <i>hTERT</i> transcription and telomerase activity, contributing to progressive telomere shortening, growth arrest, and increased apoptosis. Utilizing BioID, we characterized multiple TFs as DTX2 proximal proteins, among which NFIC functioned corporately with DTX2 in promoting <i>hTERT</i> transcription. Further analysis demonstrated that DTX2 mediated K63-linked ubiquitination of NFIC, which facilitated NFIC binding to the <i>hTERT</i> promoter and enhanced <i>hTERT</i> expression. These findings highlight a new <i>hTERT</i> regulatory pathway that may be exploited for potential cancer therapeutics.
multidisciplinary sciences